Loading data for CGTX — first visit, this takes a few seconds.
Cognition Therapeutics, Inc. (CGTX)
NasdaqCM: CGTX
· Real-Time Price · USD
1.03
+0.05 (5.10%)
At close: Sep 01, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Cognition Therapeutics, Inc. (CGTX) Stock Price, Analysis & Data
No data available
| Bid | 0.72 |
| Market Cap | 96M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.8M |
| 1.78 | |
| -0.17 | |
| n/a | |
| -4.59 | |
| P/B (ttm) | 2.91 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 12, 2025 |
| Ask | 1.31 |
| Volume | 412,573 |
| Avg. Volume (20D) | 1,343,042 |
| Open | 0.98 |
| Previous Close | 0.98 |
| Day's Range | 0.98 - 1.03 |
| 52-Week Range | 0.55 - 3.28 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studi...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2021
Employees 14
Stock Exchange NasdaqCM
Ticker Symbol CGTX
Website https://www.cogrx.com
Financial Performance
In 2025, Cognition Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -23.49M, a decrease of -30.86%.
Financial StatementsEarnings Surprise
Cognition Therapeutics has released their quarterly earnings on Aug 6, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.04 exceeds estimates by 0.02, with 63.64% YoY growth.
Cognition Therapeutics, Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2